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Oral contraceptives are rarely prescribed for women with systemic lupus erythematosus,
because of concern about potential negative side effects. In this double-blind, random-
ized, noninferiority trial, we prospectively evaluated the effect of oral contraceptives on




A total of 183 women with inactive (76 percent) or stable active (24 percent) systemic
lupus erythematosus at 15 U.S. sites were randomly assigned to receive either oral con-
traceptives (triphasic ethinyl estradiol at a dose of 35 µg plus norethindrone at a dose of
0.5 to 1 mg for 12 cycles of 28 days each; 91 women) or placebo (92 women) and were
evaluated at months 1, 2, 3, 6, 9, and 12. Subjects were excluded if they had moderate or




The primary end point, a severe lupus flare, occurred in 7 of 91 subjects receiving oral
contraceptives (7.7 percent) as compared with 7 of 92 subjects receiving placebo (7.6 per-
cent). The 12-month rates of severe flare were similar: 0.084 for the group receiving oral
contraceptives and 0.087 for the placebo group (P=0.95; upper limit of the one-sided
95 percent confidence interval for this difference, 0.069, which is within the prespecified
9 percent margin for noninferiority). Rates of mild or moderate flares were 1.40 flares per
person-year for subjects receiving oral contraceptives and 1.44 flares per person-year
for subjects receiving placebo (relative risk, 0.98; P=0.86). In the group that was ran-
domized to receive oral contraceptives, there was one deep venous thrombosis and one
clotted graft; in the placebo group, there was one deep venous thrombosis, one ocular




Our study indicates that oral contraceptives do not increase the risk of flare among
women with systemic lupus erythematosus whose disease is stable.
abstract
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oncern regarding potential neg-
 
ative effects of exogenous estrogens on the
course of systemic lupus erythematosus has
influenced prescribing practices, although placebo-
controlled trials have not been performed. The ba-
sis of reluctance to prescribe oral contraceptives is
that the incidence of systemic lupus erythematosus




 that the disease
generally presents after menarche and before meno-
















 and a retrospective study among subjects










 and, depending on the genetic back-





Despite the preceding data, there are settings in
which exogenous estrogens might provide benefit.
Premenopausal women with systemic lupus erythe-
matosus should have access to safe and effective
birth control. Women who have diminished fertility
may seek hormonal manipulation to stimulate ovu-
lation, and women receiving cyclophosphamide
may need methods for preserving fertility. Further-
more, exogenous estrogens may be used to prevent
glucocorticoid-induced osteoporosis and to treat
ovarian cysts, endometriosis, irregular menses, and
menometrorrhagia. The high rate of elective abor-
tion among women with systemic lupus erythema-
tosus (about 23 percent of pregnancies) may reflect
the failure of the birth-control method used or the




To address these issues, we initiated the Safety of
Estrogens in Lupus Erythematosus National Assess-
ment (SELENA) trial, which comprised two sepa-
rate, randomized, placebo-controlled, multicenter




 and the oth-
er of combined oral contraceptives [OC-SELENA]).
The goal of the OC-SELENA trial was to determine
the effect of oral contraceptives containing low-dose
synthetic estrogens and progestins on disease ac-
tivity in premenopausal women with systemic lupus
erythematosus. The study was designed as a non-
inferiority trial to establish that oral contraceptives
do not appreciably increase the risk of a severe flare









fore the recruitment of patients to revise the defini-
tions of the instrument used, the Systemic Lupus









three elements: the SELENA-SLEDAI score (range,
0 to 105, with 0 indicating inactive disease); an
assessment of new or worsening disease activity,
medication changes, and hospitalizations not cap-
tured with the use of the SLEDAI; and the score on
the physician’s global-assessment visual-analogue
scale (range, 0 to 3, with 0 indicating inactive dis-
ease and 3 severe disease) (for details, see the Sup-
plementary Appendix, available with the full text of
this article at www.nejm.org). The physicians at
each study site scored each element of the flare com-
posite. Mild or moderate flares and severe flares
were defined exactly as described in the recently





 Whether these definitions could
identify flares accurately and uniformly was tested
before enrollment with the use of scenarios involv-





2001, all site investigators completed this test with
the use of case-report forms of SELENA subjects,




A total of 183 women with systemic lupus erythe-
matosus were enrolled from June 1997 through
July 2002 (with follow-up through July 2003) at 15
U.S. sites (see the Supplementary Appendix). In-
stitutional review boards at all sites approved the
protocol and consent forms, and written informed
consent was obtained from subjects before enroll-
ment. Throughout the study, each site reported ad-
verse events to its local institutional review board.
In addition, all serious adverse events in the over-
all study were reported to all institutional review
boards.
At enrollment, subjects fulfilled at least four of
the criteria of the American College of Rheumatol-





 and were under 40 years of age if they
were nonsmokers or under 36 years of age if they
were smokers. All subjects had disease that was
c
methods
Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org on December 21, 2005 . This article is being provided free of charge for use in Argentina. 
 






















clinically stable or had improved in the previous
three months. Subjects were stratified as having ei-
ther inactive disease (defined as a SELENA-SLEDAI
score of 4 or less and the receipt of a daily dose of
prednisone of no more than 0.5 mg per kilogram
of body weight that had not been increased in the
previous three weeks) or stable active disease (de-
fined as a SELENA-SLEDAI score of 5 to 12 and the
receipt of a daily dose of prednisone of no more
than 0.5 mg per kilogram that had not been in-
creased in the previous three weeks). Additional
immunosuppressive drugs at enrollment were per-
mitted if the dose had been stable for the previous
two months. Exclusion criteria were the use of oral
contraceptives for more than one month after the
diagnosis of systemic lupus erythematosus; a dia-
stolic blood pressure of more than 95 mm Hg or a
systolic blood pressure of more than 145 mm Hg
on three determinations; a history of spontaneous
deep venous thrombosis, arterial thrombosis, or
pulmonary embolus; the presence of IgG, IgM, or
IgA anticardiolipin antibodies (more than 40 IgG
phospholipid units, 40 IgM phospholipid units, or
50 IgA phospholipid units), a demonstration of lu-
pus anticoagulant by the dilute Russell’s viper-
venom time test, or both; a history of gynecologic
or breast cancer; a history of myocardial infarc-
tion; hepatic dysfunction or tumors of the liver; un-
controlled diabetes; congenital hyperlipidemia;
migraines associated with neurologic sequelae;
unexplained vaginal bleeding; or a positive preg-
nancy test.
Potential subjects were informed orally by the
recruiting physician and in the written consent form
that they might receive either oral contraceptives or
identical placebo pills. To enter the study, all sub-
jects had to agree to use an alternative form of birth
control throughout the study, and any subject who





Subjects were randomly assigned in a ratio of 1:1
to receive oral contraceptives (triphasic ethinyl es-
tradiol plus norethindrone) (Ortho-Novum 7/7/7,
Ortho-McNeil) in four-week cycles (seven days of
35 µg of ethinyl estradiol plus 0.5 mg of norethin-
drone, seven days of 35 µg of ethinyl estradiol plus
0.75 mg of norethindrone, seven days of 35 µg of
ethinyl estradiol plus 1.0 mg of norethindrone, and
seven days of inert pills) or identical placebo (Ortho-
McNeil). The randomization scheme was stratified
according to study site and disease severity (stable
active vs. inactive). Permuted blocks of variable size
(2 through 8) were used within each stratum for
treatment assignments. Study drug was taken for
12 cycles of 28 days each (“months”). The study
drug (Ortho-Novum 7/7/7) and matching placebo
were provided free of charge by the manufacturer,
Ortho-McNeil; the company had no role in the ini-
tiation, planning, conduct, data assembly, analysis,
or interpretation of the study.
At screening, a history was taken and physical
examination performed. A gynecologic examina-
tion and Papanicolaou smear were required within
the year preceding enrollment. Laboratory tests in-
cluded complete blood count, metabolic panel, lipid
profile, urinalysis, and 24-hour urine collection to
measure levels of creatinine and protein excretion.
Serologic profiles included antinuclear antibodies
assayed by HEp-2 cell line, anti–double-stranded
DNA (anti-dsDNA) antibodies by enzyme-linked
immunosorbent assay (ELISA, Diamedix), and C3
and C4 by nephelometry (Dade Behring) at the Hos-
pital for Joint Diseases in New York; lupus antico-
agulant by dilute Russell’s viper-venom time test
with confirmatory mixing studies at Johns Hopkins
University in Baltimore; and anticardiolipin anti-







dent assay) at the Hospital for Special Surgery in
New York. Subjects were seen at screening and qual-
ifying visits, contacted 2 weeks after entry, and then




The primary end point was the occurrence of a se-
vere flare. Secondary end points were the occur-
rence of mild or moderate flares and score on the
SELENA-SLEDAI instrument. Pregnancy was not
considered as a statistical end point or outcome
measure but, rather, constituted a discontinua-
tion criterion. In this noninferiority trial, our de-
sign criteria were to demonstrate that oral contra-
ceptives did not increase the risk of the occurrence
of a severe flare by more than a prespecified maxi-
mum margin that was clinically acceptable, as
compared with placebo. We expected a 12-month
severe-flare rate of 6 percent in the placebo group.
Taking into consideration the potential benefits
of oral contraceptives, the SELENA investigators
deemed a priori that an absolute difference of less
than 9 percent in severe-flare rates between the
groups receiving oral contraceptives and placebo
would be clinically acceptable.
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The criterion for the establishment of the safety of
oral contraceptives was that the upper limit of the
one-sided 95 percent confidence interval for the dif-
ference in severe-flare rates between the groups had
to be less than 9 percent. It was determined that a
sample size of 350 subjects would yield 95 percent
power at a one-sided type I error rate of 0.05 to con-
clude that oral contraceptives are not inferior to pla-
cebo, assuming a noninferiority margin of 9 percent
and a 6 percent severe-flare rate in both treatment
groups. However, the SELENA data and safety
monitoring board elected to close enrollment after
183 patients had been randomly assigned, because
of difficulty in recruitment.
Distributions of time to the first occurrence of
a severe flare were estimated with the use of the
Kaplan–Meier method. The difference in 12-month
severe-flare rates between treatment groups was
computed from the difference in the correspond-
ing Kaplan–Meier estimates.
The Cox proportional-hazards model was used
to obtain estimates of the relative risk of severe flare.
Times to first occurrences of mild or moderate flares
and flares of any type were analyzed with similar
approaches. The SELENA-SLEDAI instrument score
was analyzed by computing the change from base-
line at each follow-up visit and comparing the size
of the changes between treatment groups with the
use of the two-sample t-test. Linear mixed-effects
models were also fitted to the repeated measures.
Analyses were based on the intention-to-treat
principle. Data on subjects who were lost to follow-
up were considered to be censored at the time of the
subjects’ last visit. A per-protocol analysis that was
limited to subjects who were fully adherent to the
treatment protocol was also performed to evaluate
the primary end point. P values are two-sided and





A total of 91 subjects were randomly assigned to re-
ceive oral contraceptives, and 92 subjects to receive
placebo. Figure 1 is a flow chart of the study sub-
jects; Table 1 summarizes the subjects’ clinical char-
acteristics at enrollment. Racial and ethnic back-
grounds, which were determined by the subjects,
were similar for subjects in the oral-contraceptive
group and the placebo group, respectively: white,
41 percent and 33 percent; black, 28 percent and 38
percent; Asian, 13 percent and 14 percent; Hispanic,
18 percent and 14 percent; and other groups, 1 per-
cent and 1 percent.
The 12-month nonadherence rate was 37.4 per-
cent for the oral-contraceptive group and 37.0 per-
cent for the placebo group (P=0.95). Subjects who
terminated the study drug early for any reason
other than the occurrence of a severe flare were
results
 
Figure 1. Study Subjects.
 
Seven subjects who were assigned to receive oral contraceptives (OCs) had a 
severe flare. Of those subjects, five discontinued the study drug due to severe 
flare, one had a flare after randomization but before taking the drug, and one 
had a flare after discontinuing the drug (voluntary stop). Subjects who were 
lost to follow-up are a subgroup of the subjects who discontinued drugs. All 
subjects were included in the intention-to-treat analysis. A per-protocol analy-
sis to evaluate the primary end point (the occurrence of a severe flare) was 
also performed; it included only subjects who completed 12 months of medi-
cation or who stopped medication because of the occurrence of a severe flare 
and completed 12 months of follow-up (57 in the oral-contraceptive group 
and 58 in the placebo group).
183 Randomized
91 Assigned to OC
90 Received OC
1 Did not receive OC
1 Severe flare
92 Assigned to placebo
88 Received placebo









6 Other medical problems
23 Voluntary stops






6 Other medical problems
19 Voluntary stops
18 Lost to follow-up
274 Assessed for eligibility
91 Excluded
91 Analyzed 92 Analyzed
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considered to be nonadherent. The 12-month rate
of loss to follow-up (i.e., nonadherent subjects
who dropped out completely and were not fol-
lowed for the full 12 months) was 14 percent for





The occurrence of a severe flare was infrequent in
both groups: 7 of 91 subjects in the oral-contracep-
tive group (7.7 percent) and 7 of 92 subjects in the
placebo group (7.6 percent) (Table 2). Two of the
severe flares in the oral-contraceptive group took
place when subjects were not taking the study drug
(one subject had a flare after qualifying for the
study but before taking the drug, and the other had
a flare four months after voluntarily stopping the
drug). The 12-month severe-flare rate estimated
from the Kaplan–Meier approach was 0.084 for the
oral-contraceptive group (95 percent confidence
interval, 0.024 to 0.14) and 0.087 for the placebo
group (95 percent confidence interval, 0.025 to
0.15), which was a difference of –0.0028 between
the groups (P=0.95). The upper limit of the one-
sided 95 percent confidence interval for the true
difference was 0.069, implying that the data are
consistent with an absolute difference in severe-
flare rates of up to 6.9 percent, less than the prespec-
ified equivalence margin of 9 percent. A Kaplan–
Meier estimate for the cumulative probability of the
occurrence of severe flare is provided in Figure 2.
As calculated by the Cox proportional-hazards mod-
el, the estimated relative risk of the occurrence of
severe flare while receiving oral contraceptives, as
compared with placebo,  was 0.93 (P=0.89; 95 per-
cent confidence interval, 0.33 to 2.65). Although
the sample size was reduced to 183 subjects, we
were able to demonstrate that the difference in the
risk of severe flare between the oral-contraceptive
group and the placebo group was less than the max-
imum clinically acceptable difference. Furthermore,
this finding persisted even with the hypothetical
calculation of one or two additional severe flares in
the oral-contraceptive group (data not shown).
The per-protocol analysis, which included 57
subjects receiving oral contraceptives and 58 receiv-
ing placebo, yielded an estimated 12-month rate of
severe flares of 0.088 for oral contraceptives (95
percent confidence interval, 0.014 to 0.16) and 0.12
for placebo (95 percent confidence interval, 0.037
to 0.20). The difference in the 12-month rate of
severe flares between groups was –0.033 (P=0.56).
The upper limit of the one-sided 95 percent confi-
dence interval for the true difference was 0.060,
less than the prespecified margin of 9 percent and
therefore consistent with the intention-to-treat
result that oral contraceptives are not inferior to
placebo with respect to risk of a severe flare.
In both study groups, subjects who entered the
trial with stable active disease were at increased risk
for severe flare as compared with those with inactive
disease. The estimated relative risk, adjusted for
treatment, was 3.50 (95 percent confidence inter-
val, 1.23 to 9.99; P=0.02).
Rates of mild or moderate flares did not differ
significantly between groups: 63 subjects random-
ized to receive oral contraceptives (69 percent) and
55 subjects randomized to receive placebo (60 per-
cent) had one or more mild or moderate flares. The
incidence rate for mild or moderate flares, which
included multiple flares in the same subject, was
1.40 flares per person-year for the oral-contracep-
tive group and 1.44 flares per person-year for the
placebo group (relative risk, 0.98; 95 percent confi-
dence interval, 0.76 to 1.26; P=0.86).
The probability of having at least one flare of any
type during the 12-month follow-up period was 76
 
* SELENA denotes Safety of Estrogen in Lupus Erythema-
tosus National Assessment, and SLEDAI Systemic Lupus 
Erythematosus Disease Activity Index.
 
† One patient was receiving 60 mg of prednisone.
 
Table 1. Baseline Characteristics of the Study Subjects 
















Renal disorder (%) 37 37
Low levels of complement (%) 29 25
Increased DNA binding (%) 32 22
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percent for subjects receiving oral contraceptives
and 69 percent for subjects receiving placebo, a
treatment difference of 0.07 (P=0.34; upper limit
of the one-sided 95 percent confidence interval,
0.19). The estimated relative risk in the oral-con-
traceptive group by the Cox proportional-hazards
model based on the time to the first flare of any type
was 1.09 (P=0.65; 95 percent confidence interval,
0.76 to 1.55).
The mean change in SELENA-SLEDAI scores
was not significantly different between groups at
any follow-up visit (Table 3). Linear mixed-effects
models fitted to these repeated measures found no




Serious adverse events and adverse events requir-
ing the discontinuation of study medications are
 
* SELENA denotes Safety of Estrogen in Lupus Erythematosus National Assessment, SLEDAI Systemic Lupus Erythema-
tosus Disease Activity Index, and CNS central nervous system.
† Only 3 of 14 severe flares were identified by the SELENA-SLEDAI instrument score, and in each case another criterion 
was met.
‡ Severe flare occurred after the qualifying visit but before the initiation of study drug.
§ New or worsening manifestations included central nervous system involvement, vasculitis, glomerulonephritis, myosi-
tis, thrombocytopenia (platelet count, <60,000 per cubic millimeter), or hemolytic anemia (hemoglobin level, <70 g per 
liter, or a drop in hemoglobin of >30 g per liter within two weeks), each requiring a doubling of the dose of corticosteroids 
or an increase to >0.5 mg per kilogram per day or hospitalization.
¶This condition required an increase in the dose of prednisone or its equivalent to more than 0.5 mg per kilogram per day 
or the initiation of cyclophosphamide, azathioprine, mycophenolate mofetil, or methotrexate.
 
¿ Severe flare occurred after the discontinuation of study drug.
 
Table 2. Clinical Manifestations of Severe Flares According to Treatment Group.*
Treatment and Patient Clinical Manifestation SELENA-SLEDAI Composite Criteria Fulfilled†
Oral contraceptives
 
Patient 1 Nephritis and multisystem 
flare‡
Instrument score >12
New or worsening manifestation§
Increase in dose of prednisone or addition of other drug¶
Increase in physician’s global assessment to >2.5
Patient 2 Multisystem flare Instrument score >12
New or worsening manifestation§
Increase in dose of prednisone or addition of other drug¶
Patient 3 Multisystem flare¿ New or worsening manifestation§ 
Hospitalization for lupus activity
Patient 4 Abdominal vasculitis New or worsening manifestation§ 
Increase in dose of prednisone or addition of other drug¶
Hospitalization for lupus activity
Patient 5 Thrombocytopenia New or worsening manifestation§
Patient 6 Severe rash Increase in dose of prednisone or addition of other drug¶
Patient 7 Fever New or worsening manifestation§ 




Patient 1 Nephritis Instrument score >12
New or worsening manifestation§
Patient 2 Nephritis New or worsening manifestation§ 
Patient 3 Nephritis New or worsening manifestation§
Hospitalization for lupus activity
Patient 4 Nephritis New or worsening manifestation§ 
Increase in physician’s global assessment to >2.5 
Patient 5 Pleural effusions Hospitalization for lupus activity
Patient 6 CNS involvement New or worsening manifestation§
Hospitalization for lupus activity 
Patient 7 Myositis New or worsening manifestation§
Hospitalization for lupus activity
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listed in Table 4. There were four pregnancies. One
subject in the placebo group had a positive preg-
nancy test after randomization but before receiving
placebo and delivered a healthy infant at term. Two
subjects stopped receiving the study drug after pos-
itive pregnancy tests: one subject stopped receiving
oral contraceptives at the 2-month visit and later
had a miscarriage of twins at 19 weeks’ gestation,
and one subject stopped receiving placebo at the
3-month visit and elected to terminate the preg-
nancy at 16 weeks’ gestation. An ectopic pregnancy
occurred in one subject two months after oral con-
traceptives had been discontinued owing to a rash.
Effective and safe birth control is essential to the
care of premenopausal women with systemic lu-
pus erythematosus. Hormone-based contraception
remains the most effective reversible form of birth
control and is the nonsurgical method used by most
women (both whites and blacks) between the ages





available data affirm that women with systemic lu-
pus erythematosus use oral contraceptives less often





prescribing practices. Yet, the impression that ex-
ogenous estrogens may negatively influence lupus
disease activity is not derived from any reproducible
direct evidence. The SELENA trial prospectively
evaluated the effect of oral contraceptives on lupus
disease activity. Although the sample was smaller
than was initially planned, the trial demonstrated
that contraception with the use of estrogen and
progesterone does not increase a patient’s risk of
severe or mild–moderate flare beyond a clinically
acceptable margin. The nonadherence rate was con-
sistent with rates among first-time users of oral





similar manner, the pregnancy rate of 1 percent in
subjects who were receiving oral contraceptives is




Current decision making about the use of oral
contraceptives in women with systemic lupus
erythematosus is based on lupus models in mice
and on anecdotal reports and retrospective case–
control studies in humans. Among 121,645 wom-
en in the Nurses’ Health Study, past users of oral
contraceptives had a small increase in the risk that
systemic lupus erythematosus would develop (rela-
tive risk, 1.4; 95 percent confidence interval, 0.9 to





 A recent case–control study
showed a weak association between the risk of
lupus and current or past use of oral contraceptives
(adjusted odds ratio, 1.3; 95 percent confidence in-




 In a retrospective case–control
study of subjects with lupus who had a history of




 noted flares in 9 of 26
women during the first three months after the initi-
ation of combined oral contraceptives as compared
with none of 11 women receiving progestogen-





no difference in flare rates among 31 patients with
systemic lupus erythematosus who were taking
oral contraceptives, as compared with 31 nonusers.
discussion
 
Figure 2. Kaplan–Meier Estimates of the Cumulative Probability of a Severe 
Flare in Subjects Receiving Oral Contraceptives and Placebo.
 
The difference between treatment groups in the 12-month rate of occurrence 











































* Plus–minus values are ±SD. SELENA denotes Safety of Estrogen in Lupus 
Erythematosus National Assessment, and SLEDAI Systemic Lupus Erythema-
tosus Disease Activity Index.
 
† P values are calculated with the use of a two-sided t-test. 
 
Table 3. Mean Change in the SELENA-SLEDAI Instrument Score from Baseline, 
According to Treatment Group and Month of Follow-up.*






1 75 ¡0.03±2.8 79 0.06±2.4 0.83
2 80 ¡0.16±3.2 74 0.03±2.9 0.70
3 83 ¡0.19±2.7 79 0.22±2.9 0.35
6 82 ¡0.18±2.8 75 ¡0.17±3.0 0.98
9 77 0.07±2.8 70 0.06±2.8 0.99
12 78 0.12±2.9 73 ¡0.11±2.7 0.62
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In a retrospective survey of 55 women who used
oral contraceptives after receiving a diagnosis of
systemic lupus erythematosus, 7 reported an exac-
erbation of disease, which was usually confined to





The relevance of establishing the safety of oral
contraceptives in systemic lupus erythematosus ex-
tends beyond birth control. Oral contraceptives may























 In a retrospective cohort of
702 women with lupus, fractures occurred in 12.3





 In 376 women with lupus who were ob-
served prospectively, the use of oral contraceptives





 The guidelines of the
American College of Rheumatology Task Force on
Osteoporosis recommend the administration of oral
contraceptives to prevent glucocorticoid-induced





 although this benefit
has not been prospectively evaluated in women with
systemic lupus erythematosus.
In sum, although murine models and retrospec-
tive human studies suggested that exogenous es-
trogens might exacerbate lupus disease activity, the
results of the OC-SELENA trial do not support this
inference. Oral contraceptives were not associated
with an increase in severe, mild–moderate, or total
flares over the course of one year, as compared with
placebo. These data support the use of oral contra-
ceptives containing estrogen as a birth-control
choice for patients with inactive or stable, moder-
ate systemic lupus erythematosus who are at low
risk for thrombosis.
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* This table does not include the serious adverse events that constituted severe 
lupus flares, which are listed in Table 2.
† Study medications were withdrawn owing to these events.
‡ Subject had discontinued study drug owing to severe flare at three months, 
was hospitalized for a deep venous thrombosis three months later, and died 
one year after placebo was discontinued.
§ This pregnancy does not appear in Figure 1 because pregnancy was not the 
reason study drug was discontinued; ectopic pregnancy developed two 
months after the subject stopped study drug owing to rash.
¶ One subject had an ocular thrombosis after randomization and therefore 
never received study drug; the other subject had a superficial thrombophlebi-
tis at two months, resulting in the discontinuation of study drug.
¿ One subject in the oral-contraceptive group had a positive pregnancy test at 
the 2-month visit, resulting in the discontinuation of study drug; she miscar-
ried twins at 19 weeks’ gestation. 
** One subject in the placebo group had a positive pregnancy test after random-
ization and therefore never received study drug; she delivered a healthy infant 
at term. Another subject in the placebo group had a positive pregnancy test 
at the 3-month visit, resulting in the discontinuation of placebo; she elected 
 
termination at 16 weeks’ gestation.
 








no. of patients (%)
 
Serious adverse events (requiring 
hospitalization)
15 (16) 13 (14)
Thrombosis 2 (2)† 1 (1)‡
Gastrointestinal symptoms 1 (1) 3 (3)
Gynecologic symptoms 1 (1) 1 (1)
Infection 5 (5) 4 (4)
Orthopedic surgery 3 (3) 2 (2)
Toxic encephalopathy secondary 
to phenobarbital
0 1 (1)
Suicide attempt 1 (1) 0 
Elective thymectomy 1 (1) 0 
Ectopic pregnancy 1 (1)§ 0 
Death 0 1 (1)‡
Adverse events (requiring withdrawal 
of study drug)
7 (8) 12 (13)
Thrombosis 0 2 (2)†¶
Pregnancy 1 (1)†¿ 2 (2)†**
Rash 0 2 (2)†
Gynecologic symptoms 3 (3)† 3 (3)†
Migraine 0 3 (3)†
Abnormal liver-function results 2 (2)† 0 
Development of hypertension 1 (1)† 0 
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V. Kaplan; Louisiana State University Health Sciences Center, Shreveport — L. Green and R. Brouillette; Medical College of Wisconsin, Mil-
waukee — J. Zrnic; Oklahoma Medical Research Foundation, Oklahoma City — J. James, B. Lee, and F. Shelton; Rheumatology Associates
of Long Island, Port Jefferson Station, N.Y. — D. Kaell; St. Luke’s–Roosevelt Hospital Center, New York — J.T. Merrill, R. Shriky, and A.
Shriky; University of California, Los Angeles — A. Rapkin and W. Chen; University of California, San Francisco — M. Fitzpatrick; University
of Michigan, Ann Arbor — C.J.M. Van De Ven, G. Christman, and B. Gilson; University of North Carolina at Chapel Hill — W. Meyer and B.






Masi AT, Kaslow RA. Sex effects in sys-
temic lupus erythematosus: a clue to patho-




Lahita RG, Bradlow HL, Fishman J,
Kunkel HG. Estrogen metabolism in sys-
temic lupus erythematosus: patients and





Buyon JP, Kalunian KC, Skovron ML, et
al. Can women with systemic lupus erythe-
matosus safely use exogenous estrogens?




Jungers P, Dougados M, Pelissier C, et
al. Influence of oral contraceptive therapy





Roubinian J, Talal N, Siiteri PK, Sakakian
JA. Sex hormone modulation of autoimmu-





Grimaldi CM, Cleary J, Dagtas AS,
Moussai D, Diamond B. Estrogen alters
thresholds for B cell apoptosis and activa-




Systemic lupus erythematosus in preg-




Buyon JP, Petri MA, Kim MY, et al. The
effect of combined estrogen and progester-
one hormone replacement therapy on dis-
ease activity in systemic lupus erythemato-





Bombardier C, Gladman DD, Urowitz
MB, Caron D, Chang CH. Derivation of the
SLEDAI: a disease activity index for lupus




Petri M, Buyon J, Kim M. Classification





Petri M. Musculoskeletal complications
of systemic lupus erythematosus in the





Tan EM, Cohen AS, Fries JF, et al. The
1982 revised criteria for the classification





Trussell J, Kost K. Contraceptive failure
in the United States: a critical review of the




Rosenberg MJ, Waugh MS. Oral contra-
ceptive discontinuation: a prospective evalu-





Sanchez-Guerrero J, Karlson EW, Liang
MH, Hunter DJ, Speizer FE, Colditz GA. Past
use of oral contraceptives and the risk of





Cooper GS, Dooley MA, Treadwell EL,
St Clair EW, Gilkeson GS. Hormonal and
reproductive risk factors for development
of systemic lupus erythematosus: results of a





Julkunen HA. Oral contraceptives in
systemic lupus erythematosus: side-effects





Petri M, Robinson C. Oral contracep-





Kiel DP, Felson DT, Anderson JJ, Wilson
PWF, Moskowitz MA. Hip fracture and the
use of estrogens in postmenopausal wom-





Effects of hormone therapy on bone
mineral density: results from the Postmeno-
pausal Estrogen/Progestin Interventions




Pacifici R, Rifas L, McCracken R, et al.
Ovarian steroid treatment blocks a post-
menopausal increase in blood monocyte in-





Jilka RL, Hangoc G, Girasole F, et al. In-
creased osteoclast development after estro-





Gallagher JC, Riggs BL, DeLuca HF. Ef-
fect of estrogen on calcium absorption and
serum vitamin D metabolites in postmeno-





Ramsey-Goldman R, Dunn JE, Huang
CF, et al. Frequency of fractures in women
with systemic lupus erythematosus: com-





American College of Rheumatology Task
Force on Osteoporosis Guidelines. Recom-
mendations for the prevention and treat-
ment of glucocorticoid-induced osteoporo-
sis. Arthritis Rheum 1996;39:1791-801.
 
Copyright © 2005 Massachusetts Medical Society.
 



















 figures and tables. Click on a figure or table in the full-text version 




, and then click on PowerPoint Slide for Teaching. 
A PowerPoint slide containing the image, with its title and reference citation, 
can then be downloaded and saved.
Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org on December 21, 2005 . This article is being provided free of charge for use in Argentina. 
